1.Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ Clin Mol Hepatol 2024;30:807-823
Sun Young YIM ; Sung Hwan LEE ; Seung-Woo BAEK ; Bohwa SOHN ; Yun Seong JEONG ; Sang-Hee KANG ; Kena PARK ; Hyewon PARK ; Sunyoung S. LEE ; Ahmed O. KASEB ; Young Nyun PARK ; Sun-Hee LEEM ; Michael A. CURRAN ; Ji Hoon KIM ; Ju-Seog LEE
Clinical and Molecular Hepatology 2025;31(2):669-670
2.Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ Clin Mol Hepatol 2024;30:807-823
Sun Young YIM ; Sung Hwan LEE ; Seung-Woo BAEK ; Bohwa SOHN ; Yun Seong JEONG ; Sang-Hee KANG ; Kena PARK ; Hyewon PARK ; Sunyoung S. LEE ; Ahmed O. KASEB ; Young Nyun PARK ; Sun-Hee LEEM ; Michael A. CURRAN ; Ji Hoon KIM ; Ju-Seog LEE
Clinical and Molecular Hepatology 2025;31(2):669-670
3.Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ Clin Mol Hepatol 2024;30:807-823
Sun Young YIM ; Sung Hwan LEE ; Seung-Woo BAEK ; Bohwa SOHN ; Yun Seong JEONG ; Sang-Hee KANG ; Kena PARK ; Hyewon PARK ; Sunyoung S. LEE ; Ahmed O. KASEB ; Young Nyun PARK ; Sun-Hee LEEM ; Michael A. CURRAN ; Ji Hoon KIM ; Ju-Seog LEE
Clinical and Molecular Hepatology 2025;31(2):669-670
4.Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial
Sun Young YIM ; Sung Hwan LEE ; Seung-Woo BAEK ; Bohwa SOHN ; Yun Seong JEONG ; Sang-Hee KANG ; Kena PARK ; Hyewon PARK ; Sunyoung S. LEE ; Ahmed O. KASEB ; Young Nyun PARK ; Sun-Hee LEEM ; Michael A. CURRAN ; Ji Hoon KIM ; Ju-Seog LEE
Clinical and Molecular Hepatology 2024;30(4):807-823
Background/Aims:
Combination immunotherapy, exemplified by atezolizumab plus bevacizumab, has become the standard of care for inoperable hepatocellular carcinoma (HCC). However, the lack of predictive biomarkers and limited understanding of response mechanisms remain a challenge.
Methods:
Using data from the IMbrave150plus cohort, we applied an immune signature score (ISS) predictor to stratify HCC patients treated with atezolizumab plus bevacizumab or with sorafenib alone into potential high and low response groups. By applying multiple statistical approaches including a Bayesian covariate prediction algorithm, we refined the signature to 10 key genes (ISS10) for clinical use while maintaining similar predictive power to the full model. We further validated ISS10 in an independent HCC cohort treated with nivolumab plus ipilimumab.
Results:
The study identified a significant association between the ISS and treatment response. Among patients classified as high responders, those treated with the atezolizumab plus bevacizumab combination exhibited improved overall and progression-free survival as well as better objective response rate compared to those treated with sorafenib. We also observed a significant correlation between ISS10 and response to nivolumab plus ipilimumab treatment. Analysis of immune cell subpopulations revealed distinct characteristics associated with ISS subtypes. In particular, the ISS10 high subtype displayed a more favorable immune environment with higher proportions of antitumor macrophages and activated T-cells, potentially explaining its better response.
Conclusions
Our study suggests that ISS and ISS10 are promising predictive biomarkers for enhanced therapeutic outcomes in HCC patients undergoing combination immunotherapy. These markers are crucial for refining patient stratification and personalized treatment approaches to advance the effectiveness of standard-of-care regimens.
5.Current status of ultrasonography in national cancer surveillance program for hepatocellular carcinoma in South Korea: a large-scale multicenter study
Sun Hong YOO ; Soon Sun KIM ; Sang Gyune KIM ; Jung Hyun KWON ; Han-Ah LEE ; Yeon Seok SEO ; Young Kul JUNG ; Hyung Joon YIM ; Do Seon SONG ; Seong Hee KANG ; Moon Young KIM ; Young-Hwan AHN ; Jieun HAN ; Young Seok KIM ; Young CHANG ; Soung Won JEONG ; Jae Young JANG ; Jeong-Ju YOO
Journal of Liver Cancer 2023;23(1):189-201
Background:
/Aim: Abdominal ultrasonography (USG) is recommended as a surveillance test for high-risk groups for hepatocellular carcinoma (HCC). This study aimed to analyze the current status of the national cancer surveillance program for HCC in South Korea and investigate the effects of patient-, physician-, and machine-related factors on HCC detection sensitivity.
Methods:
This multicenter retrospective cohort study collected surveillance USG data from the high-risk group for HCC (liver cirrhosis or chronic hepatitis B or C >40 years of age) at eight South Korean tertiary hospitals in 2017.
Results:
In 2017, 45 experienced hepatologists or radiologists performed 8,512 USG examinations. The physicians had a mean 15.0±8.3 years of experience; more hepatologists (61.4%) than radiologists (38.6%) participated. Each USG scan took a mean 12.2±3.4 minutes. The HCC detection rate by surveillance USG was 0.3% (n=23). Over 27 months of follow-up, an additional 135 patients (0.7%) developed new HCC. The patients were classified into three groups based on timing of HCC diagnosis since the 1st surveillance USG, and no significant intergroup difference in HCC characteristics was noted. HCC detection was significantly associated with patient-related factors, such as old age and advanced fibrosis, but not with physician- or machine-related factors.
Conclusions
This is the first study of the current status of USG as a surveillance method for HCC at tertiary hospitals in South Korea. It is necessary to develop quality indicators and quality assessment procedures for USG to improve the detection rate of HCC.
6.Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study
Chang Hun LEE ; Gwang Hyeon CHOI ; Hwa Young CHOI ; Sojung HAN ; Eun Sun JANG ; Young Eun CHON ; Young CHANG ; Kyung-Ah KIM ; Do Young KIM ; Hyung Joon YIM ; Hye-Lin KIM ; Sook-Hyang JEONG ; In Hee KIM
Clinical and Molecular Hepatology 2023;29(3):779-793
Background/Aims:
To eliminate hepatitis B virus (HBV) and hepatitis C virus (HCV) according to the World Health Organization (WHO) criteria in 2021, this study investigated the national core indicators representing the current status of viral hepatitis B and C in South Korea.
Methods:
We analyzed the incidence, linkage-to-care, treatment, and mortality rates of HBV and HCV infection using the integrated nationwide big data of South Korea.
Results:
According to data from 2018–2020, the incidence of acute HBV infection in South Korea was 0.71 cases per 100,000 population; tthe linkage-to-care rate was only 39.4%. Among those who need hepatitis B treatment, the treatment rate was 67.3%, which was less than 80% reported in the WHO program index. The annual liver-related mortality due to HBV was 18.85 cases per 100,000 population, exceeding the WHO target of four; the most frequent cause of death was liver cancer (54.1%). The annual incidence of newly diagnosed HCV infection was 11.9 cases per 100,000 population, which was higher than the WHO impact target of five. Among HCV-infected patients, the linkage-to-care rate was 65.5% while the treatment rate was 56.8%, which were below the targets of 90% and 80%, respectively. The liver-related annual mortality rate due to HCV infection was 2.02 cases per 100,000 population.
Conclusions
Many of the current indicators identified in the Korean population did not satisfy the WHO criteria for validation of viral hepatitis elimination. Hence, a comprehensive national strategy should be urgently developed with continuous monitoring of the targets in South Korea.
7.2022 Seoul Consensus on Clinical Practice Guidelines for Functional Constipation
Young Sin CHO ; Yoo Jin LEE ; Jeong Eun SHIN ; Hye-Kyung JUNG ; Seon-Young PARK ; Seung Joo KANG ; Kyung Ho SONG ; Jung-Wook KIM ; Hyun Chul LIM ; Hee Sun PARK ; Seong-Jung KIM ; Ra Ri CHA ; Ki Bae BANG ; Chang Seok BANG ; Sung Kyun YIM ; Seung-Bum RYOO ; Bong Hyeon KYE ; Woong Bae JI ; Miyoung CHOI ; In-Kyung SUNG ; Suck Chei CHOI ;
Journal of Neurogastroenterology and Motility 2023;29(3):271-305
Chronic constipation is one of the most common digestive diseases encountered in clinical practice. Constipation manifests as a variety of symptoms, such as infrequent bowel movements, hard stools, feeling of incomplete evacuation, straining at defecation, a sense of anorectal blockage during defecation, and use of digital maneuvers to assist defecation. During the diagnosis of chronic constipation, the Bristol Stool Form Scale, colonoscopy, and a digital rectal examination are useful for objective symptom evaluation and differential diagnosis of secondary constipation. Physiological tests for functional constipation have complementary roles and are recommended for patients who have failed to respond to treatment with available laxatives and those who are strongly suspected of having a defecatory disorder. As new evidence on the diagnosis and management of functional constipation emerged, the need to revise the previous guideline was suggested. Therefore, these evidence-based guidelines have proposed recommendations developed using a systematic review and meta-analysis of the treatment options available for functional constipation. The benefits and cautions of new pharmacological agents (such as lubiprostone and linaclotide) and conventional laxatives have been described through a meta-analysis. The guidelines consist of 34 recommendations, including 3 concerning the definition and epidemiology of functional constipation, 9 regarding diagnoses, and 22 regarding managements. Clinicians (including primary physicians, general health professionals, medical students, residents, and other healthcare professionals) and patients can refer to these guidelines to make informed decisions regarding the management of functional constipation.
8.Risk of Hepatitis C Virus Transmission through Acupuncture: A Systematic Review and Meta-Analysis
Myung Han HYUN ; Ji Hoon KIM ; Jeong Won JANG ; Jeong Eun SONG ; Do Seon SONG ; Hye Won LEE ; Young Youn CHO ; Gi-Ae KIM ; Eileen L. YOON ; Dong Hyun SINN ; Soon Sun KIM ; Sun Young YIM ; Hyun YANG ; Jihyun AN
The Korean Journal of Gastroenterology 2023;82(3):127-136
Background/Aims:
Chronic hepatitis C is a major risk factor for liver cirrhosis, hepatocellular carcinoma, and hepatic failure. Although traditional practices, including acupuncture, tend to increase the risk of HCV infection, the association remains controversial. Therefore, the current meta-analytical study was undertaken to evaluate the risks of acupuncture and hepatitis C transmission.
Methods:
Two researchers independently screened studies from the databases encompassing the period from inception to May 12, 2022. Baseline demographics, HCV transmission OR, and 95% CIs were extracted, pooled, and analyzed using random-effect models.Subgroup analyses utilizing study design and ethnicity were performed. Heterogeneity and publication bias were analyzed using the Higgins I2 test and funnel plots, respectively.
Results:
In all, 28 studies with 194,826 participants (178,583 controls [91.7%] vs. 16,243 acupuncture users [8.3%]) were included in the final analysis. The pooled analysis showed that acupuncture users had a significantly higher HCV transmission rate than controls with heterogeneity (OR, 1.84 [1.46–2.32]; p<0.001; I2 =80%). In the subgroup analysis, both cross-sectional case-control (n=14; OR, 1.96 [1.47–2.61]; p<0.001; I2 =88%) and cross-sectional studies (n=12; OR, 1.85 [1.32–2.61]; p<0.001; I2 =0%) showed significantly higher HCV infection rates in the acupuncture group than in the control group. Both Asian and non-Asian acupuncture users showed a higher HCV transmission risk than the controls (all Ps <0.001). No significant publication bias was observed.
Conclusions
Our findings indicate that acupuncture increases the risk of HCV transmission. Due to HCV's contagiousness, unsafe medical and social practices (including acupuncture) should be performed with caution.
9.Development and Roll-Out of A Coronavirus Disease 2019 Clinical Pathway for Standardized Qualified Care in Public Hospitals in Korea
Mi Young KWAK ; Eun Young JO ; BumSik CHIN ; Se Eun PARK ; Jun YIM ; Jung Eun LEE ; Kyung Eun JO ; Yeon-Sook KIM ; Jeong Eun LEE ; Young Kyung YOON ; Yu Bin SEO ; Su Jin JEONG ; Yu Min KANG ; Eun-Jeong JOO ; Jong Hyun YOON ; Sun Bean KIM ; Ga Yeon KIM ; Min-Kyung KIM
Infection and Chemotherapy 2022;54(2):353-359
Despite the coronavirus disease 2019 (COVID-19) vaccination roll-out, variant-related outbreaks have occurred repeatedly in Korea. Although public hospitals played a major role in COVID-19 patients’ care, difficulty incorporating evolving COVID-19 treatment guidelines called for a clinical pathway (CP). Eighteen public hospitals volunteered, and a professional review board was created. CPs were formulated containing inclusion/exclusion criteria, application flow charts, and standardized order sets. After CP roll-out, key parameters improved, such as increased patient/staff five-point satisfaction scores (0.41/0.57) and decreased hospital stays (1.78 days)/medical expenses (17.5%). The CPs were updated consistently after roll-out as new therapeutics drugs were introduced and quarantine policies changed.
10.Diagnostic Usefulness of an Ultra-Brief Screener to Identify Risk of Online Gaming Disorder for Children and Adolescents
Sun-Jin JO ; Hyunsuk JEONG ; Hye Jung SON ; Hae Kook LEE ; Seung-Yup LEE ; Yong-Sil KWEON ; Hyeon Woo YIM
Psychiatry Investigation 2020;17(8):762-768
Objective:
This study examined the diagnostic validity of a three-item ultra-brief screening tool for online gaming disorder in line with the gaming disorder criteria in the International Classification of Diseases 11th Revision.
Methods:
The Three-item Gaming disorder Test-Online-Centered (TIGTOC) was composed of three items using a four-point Likert scale selected from the Internet Game Use-Elicited Symptom Screen (IGUESS). Among a cohort of 2319 young-adolescent Internet users, the baseline data of 228 healthy controls and 45 Internet-gaming-disorder cases were analyzed. Receiver operation characteristic (ROC) analysis was performed using mental health specialists’ diagnoses as the gold standard.
Results:
The ROC curve analysis showed an area under the curve of 86%. Using a cut-off score of 4 from a full range of 0–9, the sensitivity, specificity, and Cronbach’s α were 72%, 90%, and 0.811, respectively. TIGTOC scores was positively associated with time spent on online gaming, depressive symptoms, attention-deficit/hyperactivity disorder symptoms, and addictive Internet use.
Conclusion
The TIGTOC appears to be a brief, valid, and reliable screening tool for online gaming disorder within the community or in primary care settings.

Result Analysis
Print
Save
E-mail